Herpes Simplex News and Research

RSS

Herpes simplex is a viral disease caused by herpes simplex viruses; both herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) cause herpes simplex. Infection with the herpes virus is categorized into one of several distinct disorders based on the site of infection.

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis (commonly referred to as cold sores), using NanoBio's proprietary anti-infective nanoemulsion product candidates.

5 Aug 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories ,adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

28 Jul 2010

Antigenics announces positive results of AG-707 genital herpes vaccine

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2,the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

28 Jul 2010

Scientists discover mechanism of herpes virus cell entry machinery

The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.

27 Jul 2010

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical Incorporated today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection.

26 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

Fatness drives inactivity, not the other way around

According to a recent longitudinal study in children, inactivity does not lead to fatness! Moreover, the authors concluded that fatness is driving inactivity, and not the other way around. The authors noted that this "reverse causality" explains the observed association between inactivity and fatness. It also explains the repeated failures of the attempts to reduce childhood obesity by increasing physical activity. The study was published in the Archives of Disease in Childhood by Dr. Brad Metcalf and colleagues from Plymouth, UK.

15 Jul 2010

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice - still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

FDA approves Beech Tree Labs' IND for Phase 1/2a clinical evaluation of BTL-TML-HSV

Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections. The study will be a 210 patient, multi-site, placebo-controlled trial and is anticipated to begin later this summer.

8 Jul 2010

Map of herpes virus "cell-entry machinery" provides new target for antiviral drugs

The mechanism by which a herpes virus invades cells has remained a mystery to scientists seeking to thwart this family of viruses. New research funded by the National Institutes of Health and published online in advance of print in Nature Structural & Molecular Biology reveals the unusual structure of the protein complex that allows a herpes virus to invade cells. This detailed map of a key piece of the herpes virus "cell-entry machinery" gives scientists a new target for antiviral drugs.

7 Jul 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.

28 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

HSV-1 may cause cognitive deficits: Study

Exposure to the common virus that causes cold sores may be partially responsible for shrinking regions of the brain and the loss of concentration skills, memory, coordinated movement and dexterity widely seen in patients with schizophrenia, according to research led by Johns Hopkins scientists.

29 May 2010

FDA grants 510(k) market clearance for EraGen's MultiCode-RTx HSV 1&2 Kit

EraGen Biosciences Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for EraGen's MultiCode®-RTx HSV 1&2 Kit.

20 May 2010

Herpes Simplex News and Research

Further Reading

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoBio Corporation receives U.S. patent for nanoemulsion technology

Vical second-quarter revenues decrease to $2.1 million

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

Antigenics announces positive results of AG-707 genital herpes vaccine

Scientists discover mechanism of herpes virus cell entry machinery

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Fatness drives inactivity, not the other way around

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

FDA approves Beech Tree Labs' IND for Phase 1/2a clinical evaluation of BTL-TML-HSV

Map of herpes virus "cell-entry machinery" provides new target for antiviral drugs

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

HSV-1 may cause cognitive deficits: Study

FDA grants 510(k) market clearance for EraGen's MultiCode-RTx HSV 1&2 Kit

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News